SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools (LAB) filed an S-4 registration statement for its…

STANDARD BIOTOOLS INC. · 425 filed Jul 20, 2026 at 07:55 ET

At the news

BULLISHIMPACT 7/10

425 filed Jul 20, 2026 at 07:55 ET

Standard BioTools (LAB) filed an S-4 registration statement for its all-stock reverse merger with Treeline Biosciences, a procedural milestone. The filing highlights strong Phase 1 data for Treeline's lead asset TLN-121 (84% ORR, 32% CR in heavily pretreated lymphoma patients) and confirms the combined company expects >$900M pro-forma cash at closing, funding operations into 2029. This update materially de-risks the deal by showcasing Treeline's pipeline and adding former Genentech CMO Sue Desmond-Hellmann to the board.

  • S-4 registration statement filed with the SEC, a key step toward shareholder vote and deal close
  • Combined company expected to have >$900M pro-forma cash at closing, funding operations into 2029
  • TLN-121 (BCL6 degrader) Phase 1 data: 84% ORR (16/19), 32% CR (6/19) in relapsed/refractory lymphomas, no dose-limiting toxicities
  • Interim data readouts for TLN-121 and TLN-372 planned for 2027, with more precise guidance in early 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access